Todd Foley
CIK 1473930 · last filed 2026-01-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITOS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1100
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKTS | Director | 4,002,533 | $15.73 | $62.96M | $4.19M | 1 | 2026-01-14 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 2,268,195 | $2.65 | $6.01M | -$17.12M | 17 | 2023-06-12 |
| TRDA | Director | 4,425,784 | $4.75 | $21.02M | $2.00M | 3 | 2022-06-06 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 3,041,865 | $10.15 | $30.87M | -$61.38M | 4 | 2021-11-24 |
| CHIASMA, INC (CHMA) Delisted | Director | 10,426 | $3.76 | $39.2K | $0 | 7 | 2021-08-05 |
| RYTM | Director | 909,258 | $89.47 | $81.35M | -$48.86M | 26 | 2021-03-16 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 389,842 | $23.01 | $8.97M | -$21.85M | 1 | 2021-02-04 |
| Oncorus, Inc. (ONCR) Delisted | 10%+ Owner | 2,675,677 | $0.12 | $322.6K | $18.25M | 1 | 2020-10-08 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | 10%+ Owner | 3,351,048 | — | — | -$250.2K | 2 | 2014-03-11 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Director | 62,920 | — | — | $892.9K | 1 | 2014-02-06 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Director | — | — | — | $0 | 1 | 2010-01-20 |
Recent Filings · Page 4 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-25 | Repare Therapeutics Inc. (RPTX) Delisted | Mixed | +3,003,772 | $5.00M | EDGAR |
| 2020-06-18 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2020-06-12 | CHIASMA, INC (CHMA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-05 | RYTM | Sell (S) | −1,896 | -$37.9K | EDGAR |
| 2020-06-03 | RYTM | Sell (S) | −44,358 | -$896.5K | EDGAR |
| 2020-05-28 | RYTM | Sell (S) | −29,300 | -$591.0K | EDGAR |
| 2020-05-26 | RYTM | Sell (S) | −96,921 | -$1.97M | EDGAR |
| 2020-05-20 | RYTM | Sell (S) | −34,509 | -$690.3K | EDGAR |
| 2020-05-15 | RYTM | Sell (S) | −1,837 | -$36.8K | EDGAR |
| 2020-05-12 | RYTM | Sell (S) | −53,130 | -$1.08M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.